发明名称 |
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
摘要 |
The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
|
申请公布号 |
US8236807(B2) |
申请公布日期 |
2012.08.07 |
申请号 |
US20090505725 |
申请日期 |
2009.07.20 |
申请人 |
NAKAJIMA SUANNE;MIAO ZHENWEI;SUN YING;TANG DATONG;XU GUOYOU;PORTER BRIAN;OR YAT SUN;WANG ZHE;ENANTA PHARMACEUTICALS, INC. |
发明人 |
NAKAJIMA SUANNE;MIAO ZHENWEI;SUN YING;TANG DATONG;XU GUOYOU;PORTER BRIAN;OR YAT SUN;WANG ZHE |
分类号 |
C07D401/12;A61K31/38;A61K31/395;A61K38/12;A61P31/12;C07D409/14;C07K5/08;C07K5/12 |
主分类号 |
C07D401/12 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|